



Company Contact:
Richard Gabriel
CEO and President
941 366-3400

-or-

Ron Stabiner
The Wall Street Group, Inc.
212-888-4848

FOR IMMEDIATE RELEASE:

**DNAPRINT GENOMICS ESTABLISHES NON-PROFIT
FOUNDATION TO HELP POLICE SOLVE CASES INVOLVING
DNA EVIDENCE**

*Foundation To Award Grants to Law Enforcement Agencies To Employ Cutting-Edge DNA
Technology*

SARASOTA, Fla., Dec. 11, 2007 – DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced that it has created a not-for-profit foundation to award grants, both in cash and in-kind donations of services from DNAPrint Genomics and other biotechnology companies, to law enforcement agencies having unsolved cases involving DNA evidence.

The foundation, **Beyond CODIS, Inc.**, is a Florida-based corporation that has applied for 501(c)3 exemption. The foundation will begin taking applications in January, 2008, with the first grants to be awarded in May, 2008.

In addition to awarding grants, the foundation will also conduct seminars to discuss the application of the newest advances in DNA forensic analysis, assist law enforcement agencies in providing closure to families by using DNA technology to identify unknown victims and help provide evidence at trial in order to exonerate an innocent person who has been wrongly convicted of a crime.

Interested agencies can go to the Beyond CODIS website at www.BeyondCODIS.org for updates and grant applications. The foundation will have a board of directors with academic, forensic and law enforcement experience to review and select which cases have the best potential to be solved with new technology.

CODIS is an acronym for the **Combined DNA Index System**, an FBI-funded computer software program that operates local, state, and national databases of DNA profiles from convicted offenders, unsolved crime scene evidence, and missing persons. In order to be effective, the DNA sample being tested must match or closely resemble one already in the database.

According to Richard Gabriel, CEO and President of DNAPrint Genomics, Inc., Beyond CODIS was founded to promote the use of DNA technology in solving violent crimes. "We essentially created this foundation in order to fill the gap between federal and state funding for DNA analysis," Mr. Gabriel said. "Funding is always the issue, especially with smaller law enforcement agencies so we hope that Beyond CODIS can remove some of those barriers and help police solve cases."

(more)

About DNAPrint Genomics, Inc.

DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS^(TM), RETINOME^(TM), ANCESTRYbyDNA^(TM) and EURO-DNA^(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

###